Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of “patented” ATO is prohibitive because of patent rights. “Generic” ATO has been used in a few countries, but its implic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Bankar, Aniket, Korula, Anu, Kulkarni, Uday P., Devasia, Anup J., Fouzia, NA, Lionel, Sharon, Abraham, Aby, Balasubramanian, Poonkuzhali, Janet, Nancy Beryl, Nair, Sukesh C., Sezlian, S, Jeyaseelan, Visali, Jeyaseelan, N, Prasad, Jasmine, George, Biju, Mathews, Vikram
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7617145/
https://ncbi.nlm.nih.gov/pubmed/31863602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16343
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares